Diagnosis · Ultrasound Silo · Hepatology
Hepatic steatosis on ultrasound: how fatty liver looks and what it means
Hepatic steatosis or fatty liver is the most common liver disease worldwide — and ultrasound is the most commonly used method to detect it. A guide to ultrasound findings, grades of steatosis, and when to worry
Hepatic steatosis ultrasound
Fatty liver ultrasound
NAFLD diagnosis ultrasound
Liver ultrasound Colombia
Fatty liver grades 2026
🟤
GSMED Imaging medical team — abdominal ultrasound Colombia
Based on: EASL-EASD-EASO Clinical Practice Guidelines for NAFLD/MASLD 2023, AIUM Practice Guidelines on Liver Ultrasound 2024, Younossi ZM et al. (Hepatology 2023 — MASLD epidemiology) and Dietrich CF et al. (Ultrasound in Medicine and Biology 2022 — ultrasound steatosis).
May 2026EASL 2023 · AIUM 2024 · Younossi 2023
Fatty liver (hepatic steatosis) affects 25–30% of the world's adult population and 35–40% of patients with type 2 diabetes or obesity in Colombia. Abdominal ultrasound is the initial diagnostic method of choice — non-invasive, radiation-free, affordable, and available at any ultrasound center. This guide explains what the doctor sees on the monitor when your liver has steatosis and what each finding means.
1. How a normal liver looks on ultrasound
In a normal liver, the echogenicity (brightness) of the liver parenchyma is slightly higher than that of the right kidney and similar to that of the spleen — all three organs have comparable echogenicity in a healthy person. The portal vessels are clearly visible with their bright echogenic walls. The suprahepatic veins appear as tubular structures without echogenic walls. The echogenicity of the liver is homogeneous throughout the parenchyma.
2. How fatty liver looks — ultrasound findings
✨Increased echogenicity ("bright" liver)
The most characteristic and earliest finding of steatosis. The liver with accumulated fat reflects ultrasound more than normal tissue — it appears brighter (hyperechoic) than the right kidney in the same image. In mild steatosis, the difference is subtle. In moderate-to-severe steatosis, the liver is clearly brighter than the kidney, spleen, and abdominal muscle wall.
→ Hyperechogenicity · Brighter than the kidney · Earliest finding
🌫️Posterior beam attenuation ("cloudy" image)
Fat progressively attenuates ultrasound as it penetrates the liver — deeper structures (deep portal vessels, diaphragm) appear progressively worse or disappear. In severe steatosis, the structures in the posterior part of the liver are practically invisible. This finding correlates well with the degree of steatosis quantified by biopsy.
→ Posterior attenuation · Invisible deep structures · Correlates with grade
🫀Loss of visibility of the portal veins
The walls of the portal vessels, which in a normal liver appear as bright echogenic lines, become progressively less visible in steatosis — the bright liver parenchyma "dulls" the contrast of the vascular walls. In moderate-to-severe steatosis, the portal vessels lose their walls and blend in with the parenchyma.
→ Loss of portal borders · Moderate-to-severe steatosis
📏Hepatomegaly
In many cases of moderate-to-severe steatosis, the liver is enlarged — ultrasound hepatomegaly when the longitudinal axis of the right lobe exceeds 15 cm in adults (measured on the longitudinal cut of the right lobe at the level of the midclavicular line). Not always present — fatty liver can be normal in size.
→ Axis >15 cm · Not always present · Depends on the grade
3. Grades of hepatic steatosis on ultrasound
| Grade |
% of hepatocytes with fat |
Ultrasound finding |
Clinical correlation |
| Mild (Grade 1) |
5–33% |
Mild increase in echogenicity · Slight loss of definition of portal veins · Liver slightly brighter than kidney |
Asymptomatic · Normal or minimally elevated transaminases · Reversible with lifestyle changes |
| Moderate (Grade 2) |
33–66% |
Moderate increase in echogenicity · Clear loss of definition of portal vessels · Initial posterior attenuation |
May have elevated ALT/AST · Risk of progression to steatohepatitis (MASH) if inflammation is associated |
| Severe (Grade 3) |
>66% |
Great increase in echogenicity · Portal vessels not visible · Marked posterior attenuation · Deep structures not evaluable |
Increased risk of fibrosis · Requires fibrosis assessment (elastography or biopsy) for staging |
Important limitation — ultrasound underestimates mild steatosis
Ultrasound has good sensitivity for moderate and severe steatosis (70–80%) but poorly detects mild steatosis (<33% of hepatocytes) — sensitivity of 50–60%. For precise quantification of the fat percentage, more specific techniques are used: the controlled attenuation parameter (CAP) measured with FibroScan elastography, or magnetic resonance spectroscopy (MRS) — the gold standard. Liver biopsy remains the histological reference standard.
4. Hepatic steatosis vs fibrosis — why the difference matters
Ultrasound detects fat well but is very insensitive to detecting liver fibrosis — the scarring of the liver that does determine the long-term prognosis. A liver with severe steatosis may have advanced fibrosis (F3-F4) or not — and conventional ultrasound cannot distinguish it. To assess fibrosis, liver elastography (FibroScan or ARFI), serum biomarkers (FIB-4, APRI), or liver biopsy are used. The recommendation of the EASL 2023 guidelines is to stage fibrosis in every patient with significant hepatic steatosis.
Does fatty liver cure itself or does it need treatment?
Simple hepatic steatosis (without inflammation or fibrosis) is reversible with lifestyle changes: 5–10% body weight loss, reduction in refined carbohydrate and sugar intake, regular physical activity (150 min/week of moderate intensity), and control of diabetes and dyslipidemia if present. Studies show that a 7% body weight loss resolves steatosis in 50–60% of patients. However, if there is already steatohepatitis (MASH) with significant fibrosis (F2 or more), treatment is more complex and may require specific drugs — several approved in 2024–2025 (resmetirom — Rezdiffra, FDA approved 2024 for MASH with F2-F3 fibrosis).
Ultrasound machines with liver elastography available in Colombia — GSMED
VINNO G70 and Mindray Resona I9 with ARFI elastography for liver fibrosis quantification — beyond steatosis detection.
Request information →
Sources
- EASL-EASD-EASO. Clinical Practice Guidelines for MASLD/NAFLD. easl.eu. 2023. EASL 2023
- Younossi ZM et al. MASLD epidemiology and burden. Hepatology. 2023. Younossi 2023
- Dietrich CF et al. Ultrasound assessment of liver fat content. Ultrasound Med Biol. 2022. Dietrich 2022